All News
EULAR 2017 – Day 4 Highlights
Saturday was a day of big posters and special seminars at EULAR in Madrid. In the morning, I passed on an interesting session on nailfold capillaroscopy led by Dr. M Cutolo and went to a JIA outcomes session.
Read ArticleResponder Criteria for Nonpharmalogical Treatment of Fibromyalgia.
Because of the subjective nature of fibromyalgia symptoms, tools for monitoring of disease activity and/or treatment assessment tools to evaluate effectiveness of nonpharmacological modalities are difficult to develop.
Read ArticleConcomitant Septic Arthritis and Crystalline Arthropathy
Researchers sought to describe the characteristics of patients with concurrent septic and crystal arthritis through a retrospective analysis of patients with the concomitant diagnoses between 1985-2015 at a university hospital in Spain.
Read Article
EULAR 2017 – Day 3 Highlights
Friday was a mega-day in Madrid as this day all the late-breaking abstracts were presented, in addition to the bulk of high-impact podium presentations in several areas.
Here are the major presentations from several clinical areas.
Read ArticleGuselkumab for Active Psoriatic Arthritis
A double-blind, placebo-controlled, multicenter study aimed to evaluate efficacy and safety of a fully human monoclonal anti IL-23 antibody guselkumab, in patients with active psoriatic arthritis.
Read ArticleHerpes Zoster
Today during the comorbidities in RA session, Dr. Leonard Calabrese spoke about herpes zoster (HZ).
Read ArticlePregnancy in Lupus
Young patients with systemic lupus erythematosus (SLE) get diagnosed before they have completed their families. About 30 or 40 years ago, most rheumatologists were not recommending pregnancy for their lupus patients. However, in recent times, outcomes have considerably improved.
Read ArticleThe RheumNow EULAR Week in Review – 16 June 2017
Dr. Jack Cush reviews some of the highlights from the past week at EULAR 2017 - June 16, 2017.
Follow RheumNow's expanded coverage from EULAR 2017 in Madrid.
Read Article
Gouts' Increasing Hospitalizations and Poor Management
Numerous studies have shown that gout hospitalizations have increased in the last decade. Also worrisome is a new studiy showing that patients admitted to the hospital are less likely to have received recommended urate-lowering treatment (ULT).
Read Article
EULAR 2017 – Day 2 Highlights
The heat was on at EULAR 2017 for busy presenters and attendees navigating the 104F degree temperatures at the indoor/outdoor IFEMA Convention center in Madrid.
Day 2 (Thursday) were big days for gout, drug safety, psoriatic arthritis and spondyloarthritis.
Read ArticleDigital Epidemiology
Today I came across two interesting sessions given by Gossec Laure from France and William Dixon from the United Kingdom. They talked about digital epidemiology in this changing world, as there are approximately 15 billion connected devices and more than 80,000 medical apps.
Read ArticleNew insights into the impact of pegloticase in chronic refractory gout
Pegloticase is indicated for treatment of patients with refractory gout. One major issue hampering the comfort levels of rheumatologists to use this agent is the boxed warning in the package insert regarding the documentation of anaphylaxis with the infusions. It is well known that treatment with pegloticase is associated with the development of anti-drug antibodies, which are believed to belie these reactions.
Read Articlelxekizumab Performance in TNF Nonresponders Phase 3 Trial
Lxekizumab performs well in TNF nonresponders phase 3 trial.
With more IL17 inhibitors becoming available for treatment of seronegative spondyloarthropathies, the question of efficacy and safety in different clinical scenarios arises. The phase 3 PsA SPIRIT-P2 trial involving 363 patients with PsA who failed or could not tolerate 1-2 TNFi randomized patients into 3 groups: PBO, IXE 80 mg q 2 weeks and IXE 80 mg q 4 weeks.
Normal
0
false
false
false
EN-US
X-NONE
X-NONE
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
line-height:115%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:Arial;
color:black;}
Treat-to-Target in Spondyloarthropathies
Today's session, Treat to target in axSpA: reality or utopia?, was opened with a presentation by Dr. Jurgen Braun (Herne, Germany), who masterfully reintroduced us to the treat-to-target concept in spondyloarhtropathies.
Read Article
EULAR 2017 – Day 1 Highlights
The Annual EULAR Congress kicked off this afternoon in Madrid with a number of new sessions devoted to important topics.
Read Article
Wearable Technologies Coming of Age
The first day of EULAR 2017 highlighted a symposium focus on the advances in wearable technologies. Several lectures updated attendees with the state of wearables in society and their implications on public health, fitness, weight loss and clinical trials.
Read ArticleRheumatic IRAEs Gaining Speed
Rheumatic IRAEs from checkpoint inhibitor therapy are growing rapidly in scope and rheumatologists must be aware of these complications, as they are certain to encounter this type of patient.
Read Article
Lancet Launches EULAR 2017 and "A Platinum Age of Rheumatology"
The current Lancet edition for 10 June 2017 is a rheumatology rich collection.
Read Article
Mixed Results with Combination Therapy in Gout
Lesinurad, a selective URAT-1 inhibitor has been approved for coadministration with a urate-lowering therapy (ULT) in patients with gout for nearly a year. The CRYSTAL study was one of the studies that lead to FDA approval.
Read Article
Supreme Court Decision Favors Earlier Biosimilar Adoption
On Monday June 11th, the US Supreme Court unanimously ruled that biosimilar manufacturers can bring their drugs to market faster by eliminating the provision that the biosimar manufacturer had to give the innovator company 180 days notice before launching the new biosimilar.
Read Article